Over the next decade, our aim is to transform the organisation to an innovative company with revenues being generated from the innovative portfolio of the business. Our objective will also be to build global leadership position cross our core therapy areas of dermatology, respiratory and oncology.
During the year under review, Temasek, a leading investment company based in Singapore, made an equity investment of USD 150 million in the organisation. This signicant investment reiterates the growth oriented philosophy of the organisation and our ability to keep growing the business over a long period in time.
Our US business gained traction, as we received the highest number of approvals till date in the year under review - 24 ANDAs. The slowdown in US FDA approvals for generic drugs in prior years had adversely impacted the generics market globally. As a result of increased approvals, growth rebounded after a long period of time for our US business.
Our robust pipeline of products, strong R&D capabilities, strategic manufacturing locations, along with a dynamic global team and a sound governance structure have contributed to help us emerge as a promising, integrated, research-driven global pharmaceutical company.
OUR R&D PIPELINE AND HIGHLIGHTS
We are a research driven company and have a robust pipeline of 7 novel molecules – 2 NCEs and 5 NBEs in various stages of preclinical and clinical development. We are committed to R&D and will continue the same through consistent investments in research in order to generate intellectual property assets that will help address the unmet medical needs
OUR GLOBAL ASSETS
Glenmark's commitment to uncompromising, world-class quality standards is reected in its state-of-the-art manufacturing facilities located across the globe. Glenmark has 17 manufacturing facilities, world over, which are approved by various regulatory bodies such as the US FDA, UK MHRA, WHO-GMP, Canadian TPD, South African MCC and ANVISA of Brazil.